Muytjens H L, van Veldhuizen G L, Welling G W, van der Ros-van de Repe J, Boerema H B, van der Waaij D
Antimicrob Agents Chemother. 1983 Dec;24(6):902-4. doi: 10.1128/AAC.24.6.902.
The possible use of pipemidic acid for preventing infections in granulocytopenic patients by selective elimination of the gram-negative rods from the digestive tract was evaluated. Fecal samples were collected before, during, and after therapy from 23 adults who were undergoing treatment of urinary tract infections with pipemidic acid at a dosage of 200 mg orally four times daily for 10 days. The concentration of pipemidic acid in the majority of the stool samples tested was 220 to 600 micrograms/g. However, in 19% of the samples collected on day 5, the concentration was below the detection limit (23 micrograms/ml). Approximately 90% of the fecal samples collected during or shortly after therapy were negative for members of the family Enterobacteriaceae. Resistance of the gastrointestinal tract against colonization by microorganisms from the environment (so-called colonization resistance) remained unimpaired, as measured by the absence of beta-aspartylglycine in the stool.
评估了吡哌酸通过选择性清除消化道革兰氏阴性杆菌来预防粒细胞减少患者感染的可能性。从23名正在接受吡哌酸治疗尿路感染的成年人中收集治疗前、治疗期间和治疗后的粪便样本,这些患者口服吡哌酸剂量为每日4次,每次200mg,持续10天。大多数检测的粪便样本中吡哌酸浓度为220至600微克/克。然而,在第5天收集的样本中,19%的样本浓度低于检测限(23微克/毫升)。治疗期间或治疗后不久收集的粪便样本中,约90%对肠杆菌科成员呈阴性。通过粪便中不存在β-天冬氨酰甘氨酸来衡量,胃肠道对来自环境的微生物定植的抵抗力(所谓的定植抵抗力)保持未受损。